{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001176","form_type":"8-K","ticker":"XAIR","cik":"0001641631","company_name":"Beyond Air, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.279517+00:00","generated_at":"2026-05-24T03:06:58.074236+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Beyond Air subsidiary NeuroNOS secures $2M initial funding for autism therapy development","bullets":["NeuroNOS raised $2M initial equity from private investors as part of a larger round up to $5M total.","Proceeds will accelerate preclinical development of a small-molecule drug targeting nitric oxide dysregulation in autism.","First-in-human clinical trial anticipated to begin in 2026; formulation optimization for subcutaneous injection underway.","After initial close, Beyond Air Ireland holds ~88% of NeuroNOS; would fall to ~75% if all $5M shares sold.","Drug stems from Hebrew University research showing NO inhibition improves autism phenotypes in animal models."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001176","json":"https://secwatch.observer/filing/0001641172-25-001176.json","markdown":"https://secwatch.observer/filing/0001641172-25-001176.md","text":"https://secwatch.observer/filing/0001641172-25-001176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/0001641172-25-001176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:06:58.074236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}